MedPath

A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Registration Number
NCT06094296
Lead Sponsor
Bristol-Myers Squibb
Brief Summary

The purpose of this study is to evaluate the efficacy and safety of BMS-986315 plus nivolumab in combination with platinum-based doublet chemotherapy (PDCT) versus nivolumab in combination with PDCT in the first-line treatment of Stage IV or recurrent non-small cell lung cancer (NSCLC).

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
1
Inclusion Criteria
  • Participants must have NSCLC with Stage IV or recurrent disease following multimodal therapy for locally advanced disease.
  • Study treatment must be first-line therapy for Stage IV or recurrent disease.
  • Participants in all parts of the study must have:
  • measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1. (RECIST v1.1)
  • an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  • a life expectancy of at least 3 months at the time of first dose
Exclusion Criteria
  • Untreated symptomatic central nervous system metastases
  • Participants with epidermal growth factor receptor (EGFR)/ALK receptor tyrosine kinase (ALK)/ROS proto-oncogene 1 (ROS1)/neurotrophic tyrosine receptor kinase (NTRK)/MET proto-oncogene (MET)/B-Raf proto-oncogene (BRAF)/RET proto-oncogene (RET) mutations amenable to targeted therapies
  • Participants with any known medical condition that, in the investigator's opinion, would increase the risk associated with study participation or study drug administration or interfere with the interpretation of safety results

Note: Other protocol-defined inclusion/exclusion criteria apply.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Part 2: Nivolumab + Histology-based PDCTCarboplatin-
Part 1: BMS-986315 DL 2 + Nivolumab + Histology-based PDCTBMS-986315-
Part 1: BMS-986315 DL 2 + Nivolumab + Histology-based PDCTPaclitaxel-
Part 1: BMS-986315 DL 2 + Nivolumab + Histology-based PDCTCarboplatin-
Part 2: BMS-986315 DL 2 + Nivolumab + Histology-based PDCTBMS-986315-
Part 2: BMS-986315 DL 1 + Nivolumab + Histology-based PDCTCarboplatin-
Part 2: BMS-986315 DL 1 + Nivolumab + Histology-based PDCTBMS-986315-
Part 1: BMS-986315 Dose Level (DL) 1 + Nivolumab + Histology-based PDCTBMS-986315-
Part 1: BMS-986315 Dose Level (DL) 1 + Nivolumab + Histology-based PDCTCarboplatin-
Part 1: BMS-986315 Dose Level (DL) 1 + Nivolumab + Histology-based PDCTCisplatin-
Part 1: BMS-986315 Dose Level (DL) 1 + Nivolumab + Histology-based PDCTPemetrexed-
Part 1: BMS-986315 DL 2 + Nivolumab + Histology-based PDCTPemetrexed-
Part 1: BMS-986315 Dose Level (DL) 1 + Nivolumab + Histology-based PDCTPaclitaxel-
Part 1: BMS-986315 DL 2 + Nivolumab + Histology-based PDCTCisplatin-
Part 2: Nivolumab + Histology-based PDCTPemetrexed-
Part 2: Nivolumab + Histology-based PDCTNivolumab-
Part 2: Nivolumab + Histology-based PDCTCisplatin-
Part 2: Nivolumab + Histology-based PDCTPaclitaxel-
Part 2: BMS-986315 DL 2 + Nivolumab + Histology-based PDCTNivolumab-
Part 2: BMS-986315 DL 2 + Nivolumab + Histology-based PDCTCisplatin-
Part 2: BMS-986315 DL 2 + Nivolumab + Histology-based PDCTCarboplatin-
Part 2: BMS-986315 DL 2 + Nivolumab + Histology-based PDCTPemetrexed-
Part 2: BMS-986315 DL 2 + Nivolumab + Histology-based PDCTPaclitaxel-
Part 2: BMS-986315 DL 1 + Nivolumab + Histology-based PDCTPemetrexed-
Part 2: BMS-986315 DL 1 + Nivolumab + Histology-based PDCTNivolumab-
Part 2: BMS-986315 DL 1 + Nivolumab + Histology-based PDCTCisplatin-
Part 2: BMS-986315 DL 1 + Nivolumab + Histology-based PDCTPaclitaxel-
Primary Outcome Measures
NameTimeMethod
Number of Participants With Adverse Events (AEs) for Part 1From first dose through 100 days following last dose of study treatment (assessed for approximately 7 months)

An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after signing of informed consent, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory test result), symptom, or disease temporally associated with the study intervention.

Number of Participants With Treatment Related Adverse Events (TRAEs) for Part 1From first dose through 100 days following last dose of study treatment (assessed for approximately 7 months)

An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after signing of informed consent, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory test result), symptom, or disease temporally associated with the study intervention.

Number of Participants With Serious Adverse Events (SAEs) for Part 1From first dose through 100 days following last dose of study treatment (assessed for approximately 7 months)

Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.

Number of Participants With Adverse Events (AEs) Meeting Protocol-defined Dose-limiting Toxicity (DLT) Criteria for Part 1From first dose (Cycle 1 Day 1) up to day 28

Dose-Limiting Toxicities (DLTs) are treatment effects serious enough to prevent dose increase.

Severity grades: 1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening, 5=Death

* Grade 2 uveitis or eye pain not improving or require systemic treatment

* Grade 2 pneumonitis or interstitial lung disease \>14 days

* Grade ≥ 3 uveitis, episcleritis, iritis, pneumonitis, bronchospasm or neurologic toxicity

* Grade 3 colitis not responding \>48 hours

* Hepatic abnormalities without liver metastases: serum transaminases (AST/ALT) \>5x \& ≤ 8xULN for \>2weeks, AST/ALT \>8xULN regardless of duration, total bilirubin \>3xULN, or concurrent AST/ALT \>3xULN \& total bilirubin \>2xULN

* Hepatic abnormalities with liver metastases: AST/ALT \>8x \& ≤10xULN for \>2 weeks, AST/ALT \>10xULN regardless of duration, total bilirubin \> 3xULN, or concurrent AST/ALT \>8xULN \& total bilirubin \>2xULN

* Grade 3 (hypersensitivity reaction not resolving to Grade 1 in 6 hours; fatigue \>7 days; nausea, vomiting, or diarrhea \>72 hours)

Number of Participants With Adverse Events (AEs) Leading to Discontinuation for Part 1From first dose through 100 days following last dose of study treatment (assessed for approximately 7 months)

An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after signing of informed consent, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory test result), symptom, or disease temporally associated with the study intervention.

Number of Participants Who Died in Part 1From first dose through 100 days following last dose of study treatment (assessed for approximately 7 months)

Number of participants who died during the study

Objective Response Rate (ORR) for Part 2From randomization until the date of first objectively documented progression or start of subsequent therapy whichever occurred first (planned for up to approximately 5 years)

Objective response rate (ORR) is defined as the number of participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on blinded independent central review (BICR) assessments using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), divided by the number of all randomized participants.

Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm.

Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

No participants were enrolled in Part 2 due to the study termination; therefore, no data were collected for this endpoint.

Secondary Outcome Measures
NameTimeMethod
Progression Free Survival (PFS) for Part 2From randomization until the date of first objectively documented progression or death due to any cause, whichever occurred first (planned for up to approximately 5 years)

Progression free survival is defined as the time between the date of randomization and the first date of documented progression, per blinded independent central review (BICR) assessments using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), or death due to any cause, whichever occurs first.

Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).

No participants were enrolled in Part 2 due to the study's termination; therefore, no data were collected for this endpoint.

Disease Control Rate (DCR) for Part 2From randomization until the date of first objectively documented progression or death due to any cause, whichever occurred first (planned for up to approximately 5 years)

Disease control rate (DCR) is defined as the number of participants who achieve a BOR of confirmed CR, confirmed PR, or stable disease (SD), based on BICR assessments (using RECIST 1.1) divided by the number of all randomized participants.

Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm.

Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study.

No participants were enrolled in Part 2 due to the study's termination; therefore, no data were collected for this endpoint.

Maximum Observed Serum Concentration (Cmax) for Part 2Cycle 1 Day 1, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1 (Each Cycle is of 21 Days)

Cmax is the maximum observed serum concentration.

No participants were enrolled in Part 2 due to the study's termination; therefore, no data were collected for this endpoint.

Time of Maximum Observed Concentration (Tmax) for Part 2C1D1, C1D2, C1D4, C1D8, C1D15, C2D1, C3D1, C4D1, C5D1, C5D2, C5D4, C5D8, C5D15, Day 1 of every 4 cycles from cycle 6 (up to 2 years); at 30 and 100 days post last dose (Each Cycle is of 21 Days)

Tmax is the time of maximum observed serum concentration.

No participants were enrolled in Part 2 due to the study's termination; therefore, no data were collected for this endpoint.

Number of Participants With Adverse Events (AEs) for Part 2Up to 100 days after discontinuation of study treatment

An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after signing of informed consent, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory test result), symptom, or disease temporally associated with the study intervention.

No participants were enrolled in Part 2 due to the study's termination; therefore, no data were collected for this endpoint.

Number of Participants With Treatment Related Adverse Events (TRAEs) for Part 2Up to 100 days after discontinuation of study treatment

An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after signing of informed consent, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory test result), symptom, or disease temporally associated with the study intervention.

No participants were enrolled in Part 2 due to the study's termination; therefore, no data were collected for this endpoint.

Number of Participants With Serious Adverse Events (SAEs) for Part 2Up to 100 days after discontinuation of study treatment

Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.

No participants were enrolled in Part 2 due to the study's termination; therefore, no data were collected for this endpoint.

Number of Participants With Adverse Events (AEs) Meeting Protocol-defined Dose-limiting Toxicity (DLT) Criteria for Part 2Up to 100 days after discontinuation of study treatment

Dose-Limiting Toxicities (DLTs) are treatment effects serious enough to prevent dose increase.

Severity grades: 1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening, 5=Death

* Grade 2 uveitis or eye pain not improving or require systemic treatment

* Grade 2 pneumonitis or interstitial lung disease \>14 days

* Grade ≥ 3 uveitis, episcleritis, iritis, pneumonitis, bronchospasm or neurologic toxicity

* Grade 3 colitis not responding \>48 hours

* Hepatic abnormalities without liver metastases: serum transaminases (AST/ALT) \>5x \& ≤ 8xULN for \>2weeks, AST/ALT \>8xULN regardless of duration, total bilirubin \>3xULN, or concurrent AST/ALT \>3xULN \& total bilirubin \>2xULN

* Hepatic abnormalities with liver metastases: AST/ALT \>8x \& ≤10xULN for \>2 weeks, AST/ALT \>10xULN regardless of duration, total bilirubin \> 3xULN, or concurrent AST/ALT \>8xULN \& total bilirubin \>2xULN

* Grade 3 (hypersensitivity reaction not resolving to Grade 1 in 6 hours; fatigue \>7 days; nausea, vomiting, or diarrhea \>72 hours)

Number of Participants With Adverse Events (AEs) Leading to Discontinuation for Part 2Up to 100 days after discontinuation of study treatment

An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after signing of informed consent, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory test result), symptom, or disease temporally associated with the study intervention.

No participants were enrolled in Part 2 due to the study's termination; therefore, no data were collected for this endpoint.

Number of Participants Who Died in Part 2Up to 100 days after discontinuation of study treatment

Number of participants who died during the study

No participants were enrolled in Part 2 due to the study's termination; therefore, no data were collected for this endpoint.

Area Under the Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] for Part 2C1D1, C1D2, C1D4, C1D8, C1D15, C2D1, C3D1, C4D1, C5D1, C5D2, C5D4, C5D8, C5D15, Day 1 of every 4 cycles from cycle 6 (up to 2 years); at 30 and 100 days post last dose (Each Cycle is of 21 Days)

AUC (0-T) is the area under the serum concentration-time curve from time zero to time of last quantifiable concentration.

No participants were enrolled in Part 2 due to the study's termination; therefore, no data were collected for this endpoint.

Number of Participants With Anti-drug Antibodies (ADA) to BMS-986315 for Part 2Cycle 1 Day 1, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Day 1 of every 4 cycles from cycle 6 (up to 2 years); at 30 and 100 days post last dose (Each Cycle is of 21 Days)

Number of Participants with Anti-drug Antibodies (ADA) to BMS-986315

No participants were enrolled in Part 2 due to the study's termination; therefore, no data were collected for this endpoint.

Duration of Response (DoR) for Part 2From randomization until the date of first objectively documented progression or death due to any cause, whichever occurred first (planned for up to approximately 5 years)

Duration of response is defined as the time between the date of first documented response (CR or PR) that is subsequently confirmed, to the date of the 1st objectively documented tumor progression as determined by BICR (per RECIST 1.1), or death due to any cause, whichever occurs first.

Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10mm.

Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).

Time to Objective Response (TTR) for Part 2From randomization until the date of first objectively documented progression or death due to any cause, whichever occurred first (planned for up to approximately 5 years)

Time to response (TTR) assessed by BICR is defined as the time between the date of randomization and the first confirmed documented response (CR or PR) per RECIST 1.1 criteria.

Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm.

Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

No participants were enrolled in Part 2 due to the study's termination; therefore, no data were collected for this endpoint.

Trial Locations

Locations (8)

Local Institution - 0058

🇺🇸

Boise, Idaho, United States

Local Institution - 0044

🇺🇸

Clermont, Florida, United States

Local Institution - 0049

🇺🇸

Houston, Texas, United States

Local Institution - 0040

🇺🇸

Orange City, Florida, United States

Local Institution - 0038

🇺🇸

Glendale, California, United States

Local Institution - 0032

🇦🇺

Joondalup, Western Australia, Australia

Local Institution - 0013

🇦🇺

St Leonards, New South Wales, Australia

Local Institution - 0021

🇦🇺

Tweed Heads, New South Wales, Australia

© Copyright 2025. All Rights Reserved by MedPath